Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $642.8m (+5.2%); operating margin -9.5%; net loss $43.5m.
Revenue includes $44.1m patent settlement; underlying revenue fell 2%. No debt.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
May 2025: 10x Genomics announced it would lay off 93 workers in Pleasanton, California, amid cost cuts. May 2026: it moved to settle patent litigation with Curio and filed a new patent suit against Element Biosciences, which says it strongly disagrees.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving 10x Genomics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Life-science research tools supplier; no product recalls, FDA warning letters or clinical safety actions involving 10x Genomics found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
Aug 2026: 10x Genomics reported Q2 2026 revenue of $151.0m, down from $172.9m a year earlier mainly due to lower patent settlement income, and raised full-year guidance. No notable customer disputes or terminations found in HSH's search of the last 24 months.